In a Swedish multicenter, comparative, retrospective study, patients with different types of infections--bacteremia-septicemia, genitourinary, intra-abdominal, central nervous system, and lower respiratory tract infections--were randomly selected from the hospital records. Patients treated with cefotaxime twice or three times a day as monotherapy (excluding metronidazole) for at least 1 day (240 cases) were analyzed in terms of clinical and bacteriologic outcome, these results were correlated with the dosing regimen. Similarly high success rates (cure and improvement) at hospital discharge were observed in both group initially treated with cefotaxime 1 g twice daily and 2 g twice daily (97 and 96%, respectively). A total of 73% of patients were initially treated with cefotaxime for only 3 days at most before changing to a lower dose regimen, an alternate intravenous treatment, or oral drug follow-up. Clinical evaluation at hospital discharge revealed a clinical success rate between 87 and 100%, depending on the type of infection.